Centrient Pharmaceuticals
Sustainability Report and Carbon Intensity Rankings
Is Centrient Pharmaceuticals doing their part?
Their DitchCarbon score is 66
Centrient Pharmaceuticals has a DitchCarbon Score of 66, indicating a moderate level of sustainability in their operations. This score reflects the company’s efforts to manage its carbon intensity, suggesting they are taking steps to reduce greenhouse gas emissions. A higher score would denote even greater success in lowering carbon intensity and enhancing sustainability practices.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Centrient Pharmaceuticals is part of the industrial manufacturing sector, which has a very low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Centrient Pharmaceuticals is located in the Netherlands, which has a very low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by reducing the carbon footprint associated with their operations.
Unlock 30+ emissions data points on Centrient Pharmaceuticals
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Centrient Pharmaceuticals
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
24.71%
...this company is doing 24.71% better in emissions than the industry average.
Centrient Pharmaceuticals, headquartered in Rotterdam, Netherlands, was founded in 1869 and operates within the industrial manufacturing sector. As a global leader in sustainable antibiotics, next-generation statins, and anti-fungals, the company specializes in developing, producing, and selling intermediates, active pharmaceutical ingredients, and drug products. With a worldwide presence, including manufacturing sites and sales offices across China, India, Egypt, Spain, the USA, and Mexico, Centrient Pharmaceuticals is wholly owned by the global investment firm Bain Capital.
emission intelligence's platform recommendations for Centrient Pharmaceuticals
Centrient Pharmaceuticals could potentially reduce their emissions by 20% by transitioning to renewable electricity sources, such as purchasing renewable energy certificates or engaging in direct power purchase agreements.
Good news, Centrient Pharmaceuticals has embraced SBTi commitments
Centrient Pharmaceuticals has pledged to reduce its carbon emissions in line with the Science Based Targets initiative. This commitment involves aligning their business operations with the goal of limiting global warming and pursuing sustainable practices.
Participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.